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 Abstract 
This report attempts to frame the debate about clinical administration of sodium bicarbonate in 
the setting of lactic acidosis in terms of simple questions. Specifically, we address why we 
develop lactic acidosis in some circumstances, how acute lactic acidosis impairs cardiovascular 
function and why sodium bicarbonate may have deleterious effects which limit its utility. We 
also attempt to explore treatment alternatives to sodium bicarbonate 
Keywords 
lactic acidosis, sodium bicarbonate, carbicarb 
Introduction 
The treatment of lactic acidosis remains controversial. Although many in vitro and animal 
studies were performed over the past 40 years, there is still a dearth of clinical data addressing 
simple questions such as whether sodium bicarbonate therapy is deleterious or beneficial or 
whether alternative buffers such as tris (hydroxymethyl)aminomethane (THAM) or a 
combination of sodium bicarbonate with disodium carbonate (Carbicarb) offer advantages to 
patients. In this report we will attempt to highlight the key issues that may be useful in the design 
of subsequent clinical treatments and studies. To this end, we plan to frame and answer some 
very simple questions. 
 
Why do we generate lactic acidosis? 
The end product of anaerobic glycolysis is pyruvate, which can be metabolized to carbon dioxide 
by the energy efficient Krebs cycle in the mitochondria. Alternatively, pyruvate can be 
metabolized by an energy inefficient pathway by the enzyme lactate dehydrogenase to lactate: 
  
(Pyruvate + NADH + H+ ↔ lactate + NAD⁺) 
 
Lactic acidosis, one consequence of the shock state is associated with cellular dysfunction and is 
a predictor of mortality and morbidity.1-3  Together with diabetic ketoacidosis, it accounts for 
approximately 85% of the cases of acute severe metabolic acidosis.4  The major causes of lactic 
acidosis are typically divided into disorders associated with tissue hypoxia (type A) and 
disorders in which tissue hypoxia is absent (type B). Cardiogenic or hypovolemic shock, severe 
heart failure, severe trauma and sepsis are the most common causes of type A lactic acidosis.5 
Normally, approximately 1400 mmol of lactic acid are produced daily, primarily by skeletal 
muscle and gut. The production of lactic acid is balanced by the metabolism of an equivalent 
amount of the compound in the liver, which constitutes the Cori cycle. Other tissues including 
the kidneys are capable of metabolizing lactate as well. In humans, the kidneys contribute 
approximately 10-20% of lactate removal.6  On the other hand, tissue hypoxia results in 
excessive lactate production which can increase under pathological conditions nearly 100 fold.6  
 
Lactate removal takes place via its oxidation to pyruvate by lactate dehydrogenase. Pyruvate may 
be either oxidized to carbon dioxide producing energy or transformed into glucose through 
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gluconeogenesis. Pyruvate oxidation requires oxygen supply and the cooperation of pyruvate 
dehydrogenase, the tricarboxylic acid cycle, and the mitochondrial respiratory chain. Congenital 
or acquired deficiencies in gluconeogenesis including tissue hypoxia may induce lactate 
accumulation.7  Impaired mitochondrial oxidative function, as occurs in hypoxic states, leads to 
accumulation of pyruvate in the cytosol and thus to increased lactate production. The 
accumulation of pyruvate in the hypoxic state reflects both overproduction of pyruvate and 
reduced utilization of pyruvate through its two pathways, the oxidative decarboxylation to 
acetyl-coenzyme A (acetyl-CoA) and gluconeogenesis.8  
 
Is the development of acidosis a “bad” thing? 
Clearly there are some “good” things about acidosis. On a tissue level, a moderate degree of 
acidosis allows for greater delivery of oxygen, the shortage of which often underlies the basic 
pathophysiology of lactic acidosis (see above).  Acidosis also appears to decrease the ongoing 
rate of lactic-acid generation (or ketoacid generation). This negative feedback attenuates the net 
degree of acidemia.9 
 
However, if we examine the effect of acidosis on the heart and the vascular system, one must 
conclude that it is generally deleterious. In cardiac cells, the drop in intracellular pH is known to 
have deleterious effects on myocardial contractile function.9-11  This has been clearly shown in 
the isolated perfused rat heart.12  Schotola, et al studied the effect of incremental dose of the beta 
agonist isoproterenol on human ventricular trabeculae at pH 7.20 and 7.40.  They observed a 
reduction in cardiac contractility and rightward shift of the isoproterenol dose response curve at 
pH 7.20.13,14  In intact animals, compensatory mechanisms related to the neuroendocrine 
response initially maintain cardiac output, but ultimately cardiac output falls with severe 
acidosis15,16  as we discuss below.   
  
Several cellular and functional processes have been implicated in the pathogenesis of cardiac 
contractile dysfunction in severe acidemia. These include impairment of energy production, 15,17 
disturbances in intracellular calcium transport and cycling,18-24 and  impairment of actin-myosin 
cross-bridge cycling by inorganic phosphate (Pi) and H⁺ accumulation.25  In myocardial cells 
metabolic acidosis results in increased energy demand that exceeds energy production.15  This 
discrepancy between demand and production of energy is evidenced by decreases in creatinine 
phosphate (PCr) and reciprocal increases in inorganic phosphate (Pi) beyond what would be 
expected from the calculated increases in [H+].16  The decrease in energy production in the 
isolated perfused heart appears to be the result of inhibition of the mitochondrial oxidative 
phosphorylation more than direct effects on glycolysis through allosteric effects on 
phosphofructokinase.17 
 
Intracellular pH also has a considerable impact on the amplitude of the systolic calcium transient 
and subsequent excitation-contraction coupling pathway. The net impact of intracellular acidosis 
is an increase in the calcium transient amplitude due to increased sarcoplasmic reticulum calcium 
content which subsequently affects the excitation-contraction coupling pathway. It was also 
demonstrated that global acidosis or ischemia modifies Cai
2+ cycling in myocytes causing a rise 
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in the diastolic Cai
2+ and prolongation of the cellular calcium transient characterizing a potential 
pro-arrhythmic state.26  
 
As mentioned earlier, it is apparent that the sympathoadrenal system constitutes an important 
aspect of the heart's response to acidosis.27  Increased release of catecholamines in response to 
the acidic environment from cardiac nerve endings and adrenal medulla was observed but 
myocardial responsiveness to catecholamines was found to be altered along with markedly 
enhanced vagal stimulation.28-32  Mitchell et al demonstrated that in moderate acidosis (pH > 
7.2), there is actually an increase in the maximal rate of left ventricular pressure (max dp/dt) and 
stroke volume related to the increased catecholamine levels, but with severe acidosis, the 
contractile state of the left ventricle is significantly depressed.27  Teplinsky and colleagues 
showed that experimental lactic acidosis caused a 40% reduction in stroke volume without 
reducing venous return in animals suggesting impaired myocardial contractility.33  Davies 
demonstrated that human beta 2-adrenergic receptors were altered in an in vitro model of lactic 
acidosis accompanied by resistance to the inotropic and vasoconstrictive effects of infused 
catecholamines.34  In another study by Kellum and colleagues, moderate and severe acidosis 
caused hypotension in animals without affecting plasma levels of inflammatory markers.35 
Conduction abnormalities which predispose to ventricular arrhythmias are often found in animal 
models of metabolic acidosis. This finding can explain the ventricular irritability observed during 
myocardial ischemia.36 
 
If acidosis is “bad,” why isn’t the administration of sodium bicarbonate “good?” 
It is very clear that therapy directed to the specific cause of the acidosis is rational. Clinical 
outcomes are in fact quite good when such intervention effectively normalizes the production of 
acid as is the case with diabetic ketoacidosis and some cases of toxic alcohol ingestion where the 
process of organic acid production can be stopped. On the other hand, conditions presenting with 
type A lactic acidosis and associated circulatory disturbances and tissue hypoxia as in sepsis or 
cardiac arrest seem to require addressing the acidosis directly. In fact, given the potential 
deleterious effects of severe acidosis, some experts recommend intravenous sodium bicarbonate 
therapy although its value in reducing mortality or improving hemodynamics remains unproven.5  
 
Questioning the utility of bicarbonate therapy began in the late 1970s with the observation in 
experimental lactic acidosis that bicarbonate therapy worsened outcomes. In animal models of  
lactic acidosis, administration of NaHCO3 increased lactate production by the splanchnic bed.37  
Graf et al38 compared the effect NaHCO3 therapy in dogs with hypoxic lactic acidosis with the 
effects of sodium chloride or no therapy. Treatment with NaHCO3 was associated with decreases 
in cardiac output and blood pressure compared with the other two groups. Moreover and despite 
the infusion of NaHCO3, both arterial pH and bicarbonate concentration decreased by a similar 
amount in all three groups of dogs. This was postulated to result primarily from a paradoxical 
intracellular acidosis resulting from the rapid equilibrium of CO2 across the cell membrane and 
the delayed equilibration of bicarbonate.39  Other possible adverse effects of sodium bicarbonate 
therapy include hypertonicity and delayed metabolic alkalosis,32,40 but the paradoxical 
intracellular acidosis is probably the most important. Graf and colleagues measured intracellular 
liver pH with DMO distribution and found bicarbonate actually lowered this value in their 
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animal model.38  This has been confirmed using other methods of intracellular pH 
determination.12,15,16,41  To fully understand this, we can look at what happens when the 
bicarbonate buffer system is open vs. closed.   
 
In an open system (i.e., when tissue perfusion and pulmonary ventilation is adequate), CO2 
tension is controlled by the brain stem through respiratory drive and the CO2 which is generated 
from oxidative metabolism of carbon containing organic compounds and the dehydration of 
H2CO3 by carbonic anhydrase (figure 1) is eliminated by the lungs. This has been shown in both 
experimental animals42 and humans43.  Such a system can be modelled experimentally using an 
instrument called a tonometer where the CO2 tension can be held constant.44 However, when 
tissue perfusion and/or pulmonary ventilation are compromised as occurs during circulatory 
shock, the clinical scenario more closely approximates a closed system. A simple model for a 
closed system is a glass syringe with a gas tight rubber stopper.45 
 
Figure 1: Schematic illustrating effects of sodium bicarbonate (HCO3-) administration into an   
acidotic milleiu. Other abbreviations: H+ -  protons, H2CO3 carbonic acid, CO2 –    
carbon dioxide, CA – carbonic anhydrase.   
 
Kimmoun et al46 investigated the cardiovascular and metabolic effects of an adaptive sodium 
bicarbonate therapy, including ventilation of CO2 increase with hyperventilation and ionized 
calcium decrease with calcium administration. Their strategy normalized extra- and intracellular 
pH, improved cardiac elastance and improved aortic and mesenteric vasoactivity compared with 
controls. Small studies have shown promising results when high dose bicarbonate was 
administered via continuous venovenous hemofiltration to treat acidosis and renal failure.47,48  
The harmful effect of bicarbonate-induced widespread intracellular acidosis on cellular and 
metabolic function, particularly the heart, suggests that alternative buffers compatible to 
bicarbonate but without the CO2 generating potential might offer clinical advantages.   
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 Alternative Buffers 
In an effort to overcome the side effects of sodium bicarbonate, other alkali therapies have been 
developed. THAM, (tris-hydroxymethyl-aminomethan), dichloroacetate and Carbicarb constitute 
the most prominent molecules in this context. THAM was first introduced into clinical practice 
in 1959.49  30% of this compound exists in the nonionized form where it can penetrate cells and 
thereby raise the intracellular pH by buffering protons by virtue of the ammonia moiety.40  In 
experimental studies, THAM was found to have a comparable buffering capacity to bicarbonate 
but without intracellular acidosis.50  Moreover, THAM was found to have a favorable effect on 
myocardial contractility when used in dogs with lactic acidosis51  as well as in perfused isolated 
heart model during metabolic acidosis52 (pH=7.0).  
 
Clinical trials assessing THAM in patients with lactic acidosis are limited. Hoste and colleagues 
showed that administration of THAM to patients in ICU with mild metabolic acidosis was as 
effective as sodium bicarbonate.53  Further studies looking at outcome and cardiovascular 
function are needed to examine the use of THAM in the treatment of acute metabolic acidosis.               
THAM has considerable side effect profile including hepatic failure and hyperkalemia. 
Moreover, THAM is excreted by the kidney in its protonated form. Therefore, its usefulness 
would appear to be limited to acidosis in the presence of significant renal failure.40  
 
Dichloroacetate (DCA) is another investigational drug that has been studied in lactic acidosis. 
DCA exerts multiple effects on pathways of intermediate metabolism resulting in stimulation of 
peripheral glucose utilization and inhibition of gluconeogenesis.54  In lactic acidosis, DCA is 
believed to facilitate the oxidation of lactate by stimulating the activity of pyruvate 
dehydrogenase. In healthy volunteers during incremental exercise, DCA resulted in the reduction 
of blood lactate accumulation accompanied by reduction in pulmonary CO2 output without 
enhancing exercise tolerance.55  However, in a randomized controlled trial in patients with lactic 
acidosis, DCA resulted in statistically significant but clinically unimportant changes in arterial-
blood lactate concentrations and pH and fails to alter either hemodynamics or survival.56  DCA is 
not currently available in the United States for clinical use. 
 
Carbicarb, a mixture of equimolar quantities of sodium bicarbonate and sodium carbonate was 
first formulated in 1983 by Filley and Kindig.57  Sodium carbonate in the mixture reacts with 
carbonic acid (H2CO3) to generate bicarbonate via the following reaction.45,57  
 
CO3⁻² + H2CO3 ↔ 2 HCO3⁻ 
 
Thus, the carbonate component of Carbicarb consumes CO2 while the HCO3⁻ component and 
the newly generated HCO3⁻ will form CO2 when protons are buffered. At the cellular level, 
systemic [administration of] Carbicarb to treat severe acidosis resulted in systemic alkalinization  
without major changes in PaCO2 and intracellular pH in hepatocytes16, isolated heart12,58,59 and 
brain cells41 compared with NaHCO3 therapy which resulted in paradoxical intracellular 
acidosis. In animals [with lactic acidosis], Carbicarb was found to be superior to NaHCO3 with 
improved tissue pH, lactate production and cardiac hemodynamics.60  In healthy volunteers, 
Carbicarb was associated with transient decrease in PaCO2 compared with sodium bicarbonate.43  
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In a study of 36 patients undergoing surgery who developed mild acidosis, Carbicarb was found 
to be safe and comparable to NaHCO3.61  Controlled studies of the impact of Carbicarb in 
patients with severe acidosis have not been reported and the drug is not currently available in the 
United States. 
 
Carbicarb is an efficient buffer that does not cause intracellular acidosis. It has the potential for 
treating acute acidosis without impairing cellular and cardiac function. Each molecule of 
CO3⁻²will effectively eliminate one hydrogen ion in the blood, thereby directly lowering the 
proton concentration and raising pH. In addition, HCO3⁻, the product of CO3⁻²buffering is the 
main component of the sodium bicarbonate solution that is safe in humans and has excellent 
cellular permeability. On the other hand, Carbicarb can be damaging to the adjacent tissues after 
injection due to its hypertonic nature and the high level of alkalinity.62 Moreover, stability 
problems with the mixture and the proposed delivery syringe have slowed its entry into the 
clinic. Specifically, the extremely high pH of Carbicarb appears to degrade the rubber stoppers 
which can safely be used to seal bicarbonate ampules (unpublished observations). 
 
Simulations of different combinations of bicarbonate and carbonate: 
As mentioned above, Carbicarb, like THAM, was developed with the aim of avoiding 
“paradoxical” intracellular acidosis. To examine what changes in PaCO2 and pH might be 
anticipated, we performed the following simulations guided by the observed responses seen with 
closed and open systems.45  Specifically, we found in the past that when bicarbonate was added 
to a closed system, we observed very little change in pH but rather marked increases in PaCO2. 
In contrast, the addition of carbonate to a closed system resulted in the rapid consumption of 
CO2 as new HCO3 was generated. Using these principles and the known values for CO2 
solubility and the equilibrium constant for the H2CO3 – HCO3- system, simulations were 
performed using the programming language MatlabTM (R2014a, the Mathworks, Inc.,) using 
code detailed in Appendix 1.    
  
We first examined the effects of NaHCO3 addition in an “open” system where PaCO2 was 
maintained at 40 torr. Bicarbonate caused no changes in PaCO2 (by definition, figure 2a) and 
increase in final pH in proportion to the change in HCO3- (figure 2b). In such a system, addition 
of carbonate was twice as potent as bicarbonate as the reaction CO3⁻² + CO2 → 2 HCO3⁻ 
predicted, but no qualitative differences were noted (data not shown). In contrast, when 
bicarbonate was added to a closed system, increases in PaCO2 were seen in proportion to the 
initial [H+] with essentially no change in pH as we observed in the aforementioned experimental 
publication45, (figures 2c and 2d, respectively). Disodium carbonate however was a very 
effective alkalinizing agent over a wide range of pH values (figure 3 panel a and b). When we 
looked at varying the proportion of carbonate to bicarbonate in a mixture, it appeared that CO2 
neutrality was achieved at relatively low proportions of carbonate, especially when the initial 
PaCO2 was high (figure 4, panels a and b).   
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                                      Figure 2a 
 
                                     Figure 2b 
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                                      Figure 2c 
 
                                     Figure 2d 
Figure 2: Simulated changes in PaCO2 and pH in open and closed system following addition of  
HCO3- (0 – 10 meq/l) with starting PaCO2 of 40 torr and initial pH (6.4 to 7.0). Panels     
2a and 2b show PaCO2 and pH (respectively) in open system and Panels 2c and 2d 
show PaCO2 and pH (respectively) in closed system.  
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                                      Figure 3a 
 
                                      Figure 3b 
 
Figure 3: Simulated changes in PaCO2 (Panel 3a) and pH (Panel 3b) in a closed system following  
addition of disodium carbonate (0-4 mmol/l) with initial pH varied between 6.4 and 7 
with initial PaCO2 of 100 torr.  
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                                      Figure 4a 
 
 
                                     Figure 4b 
Figure 4: Simulated changes in PaCO2 (Panel 4a) and pH (Panel 4b) in a closed system following  
addition of a mixture of disodium carbonate and sodium bicarbonate (total 2 mmol/l of 
carbonate + bicarbonate) with initial pH varied between 6.4 and 7 with initial PaCO2 
of 100 torr. 
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Conclusions: 
It is very clear that, while cardiovascular function is embarrassed by acute lactic acidosis, 
treatment with sodium bicarbonate may have deleterious effects that appear largely related to its 
propensity to generate CO2 in a closed system. As there is no accepted methodology for 
assessing whether the patient’s milieu is more closely approximated by a closed or an open 
system, it is very difficult to advise physicians whether or how to administer sodium bicarbonate 
in the clinical setting of lactic acidosis. Although some experimental buffers have been 
developed which appear promising, further clinical proof is necessary before their use can be 
advocated. Our simulations showed that solutions containing carbonate to bicarb ratios less than 
1:1 might be useful In treating lactic acidosis. It needs to be examined if these solutions with 
different ratios will differ from carbicarb in terms of stability and administration issues.”  
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 Appendix 1: MatlabTM code 
%bicarbonate addition simulation open 
for i=1:100 
    HCO3m(i)=4+i/10; 
    aHCO3(i)=i/10; 
    pCO20=40; 
   end 
for i=1:100 
    for j=1:100 
         pH(i,j)=6.1+log10(HCO3m(i)+ aHCO3(j))/1.2; 
         pCO2(i,j)=40; 
    end 
end 
mesh(aHCO3,pH(:,1),pH) 
axis([0 10 6.6 7.2 6.6 7.2]) 
xlabel('added bicarbonate (mmol/l)') 
ylabel('initial pH') 
zlabel('final pH') 
figure 
mesh(aHCO3,pH(:,1),pCO2) 
axis([0 10 6.6 7.2 30 150]) 
xlabel('added bicarbonate (mmol/l)') 
ylabel('initial pH') 
zlabel('final PaCO2 (torr)') 
  
 
%bicarbonate addition simulation open 
for i=1:100 
    HCO3m(i)=14+i/10; 
    aHCO3(i)=i/10; 
    pCO20=140; 
    pH(i,1)=6.1+log10(HCO3m(i)/(pCO20*0.03)); 
   end 
for i=1:100 
    for j=1:100 
         pCO2(i,j)=((HCO3m(i)+aHCO3(j))*10^-pH(i,1))/(0.03*10^(-6.1)); 
         pH(i,j)=6.1+log10(HCO3m(i)/(0.03*pCO2(i,j))); 
    end 
end 
mesh(aHCO3,pH(:,1),pH) 
%axis([0 10 6.6 7.2 6.6 7.2]) 
xlabel('added bicarbonate (mmol/l)') 
ylabel('initial pH') 
zlabel('final pH') 
figure 
mesh(aHCO3,pH(:,1),pCO2) 
%axis([0 10 6.6 7.2 30 150]) 
xlabel('added bicarbonate (mmol/l)') 
ylabel('initial pH') 
zlabel('final PaCO2 (torr)') 
 
 
%carbonate addition simulation closed 
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pCO20=140; 
keq=1.2/((40e-6)*24); 
  
for i=1:100 
    HCO3m(i)=8+i/10; 
    CN(i)= i/25; 
   end 
for i=1:100 
     
    for j=1:100 
        x=pCO20*0.03; 
        a=HCO3m(i)+ 2*CN(j); 
        z=6.1+log10(a/x); 
        x=x-CN(j); 
        z=6.1+log10(a/x); 
        x=1000*a*keq*10^-z; 
        z=6.1+log10(a/x); 
        x=1000*a*keq*10^-z; 
                     
         pH(i,j)=z; 
         PCO2(i,j)= x/0.03;  
    end 
end 
mesh(CN,pH(:,1),pH) 
%axis([0 1.0 6.6 7.2 6.6 8.0]) 
xlabel('added carbonate (mmol/l)') 
ylabel('initial pH') 
zlabel('final pH') 
figure 
mesh(CN,pH(:,1),PCO2) 
%axis([0 1.0 6.6 7.2 0 40]) 
xlabel('added carbonate (mmol/l)') 
ylabel('initial pH') 
zlabel('final PaCO2 (torr)') 
 
 
 
 
 %mixture of carbonate/bicarbonate closed 
pCO20=140; 
keq=1.2/((40e-6)*24); 
d=input('enter dose of bicarbonate/carbonate mixture'); 
  
%set up intial bicarb concentrations and fraction of carbonate 
for i=1:100 
    HCO3m(i)=12+i/10; 
    FCN(i)= (i-1)/100; 
end 
    
% develop simulations 
for i=1:100 
     
    for j=1:100 
        % initial H2CO3 
        x=pCO20*0.03; 
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        %reaction of carbonate with CO2 generating new bicarbonate 
        a=HCO3m(i)+ 2*d*FCN(j); 
        % new pH 
        z=6.1+log10(a/x); 
        % reduction in CO2 tension from carbonate 
        x=x-2*d*FCN(j); 
        %new pH 
        z=6.1+log10(a/x); 
        %new H2CO3 based on bicarbonate addition 
        x=1000*a*keq*10^-z; 
        %new pH 
        z=6.1+log10(a/x); 
        %recalculate H2CO3 
        xx=1000*(a+d*(1-FCN(j)))*keq*10^-z; 
        %recalculate pH 
        z=6.1+log10(a/xx); 
        %enter data into matrices 
         pH(i,j)=z; 
         PCO2(i,j)= xx/0.03;  
    end 
end 
%plots 
mesh(FCN,pH(:,1),pH) 
%axis([0 1.0 6.6 7.2 6.6 8.0]) 
xlabel('fraction carbonate') 
ylabel('initial pH') 
zlabel('final pH') 
figure 
mesh(FCN,pH(:,1),PCO2) 
%axis([0 1.0 6.6 7.2 0 40]) 
xlabel('fraction carbonate') 
ylabel('initial pH') 
zlabel('final PaCO2 (torr)') 
  
  
  
 
 
  
  
 
 
  
  
 
 
66
Khitan, et al.: Alkali Therapy in Lactic Acidosis
Published by Marshall University's Joan C. Edwards School of Medicine, 2015
 References: 
1. Jung B, Rimmele T, Le Goff C, Chanques G, Corne P, Jonquet O, Muller L, Lefrant JY, Guervilly C, 
Papazian L, Allaouchiche B and Jaber S. Severe metabolic or mixed acidemia on intensive care unit 
admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study. 
Crit Care. 2011;15:R238. 
2. Kraut JA and Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev 
Nephrol. 2010;6:274-85. 
3. Lee SW, Hong YS, Park DW, Choi SH, Moon SW, Park JS, Kim JY and Baek KJ. Lactic acidosis not 
hyperlactatemia as a predictor of in hospital mortality in septic emergency patients. Emerg Med J. 
2008;25:659-65. 
4. Gabow PA, Kaehny WD, Fennessey PV, Goodman SI, Gross PA and Schrier RW. Diagnostic importance 
of an increased serum anion gap. N Engl J Med. 1980;303:854-8. 
5. Kraut JA and Madias NE. Lactic acidosis. N Engl J Med. 2014;371:2309-19. 
6. Luft FC. Lactic acidosis update for critical care clinicians. J Am Soc Nephrol. 2001;12 Suppl 17:S15-9. 
7. Adeva-Andany M, Lopez-Ojen M, Funcasta-Calderon R, Ameneiros-Rodriguez E, Donapetry-Garcia C, 
Vila-Altesor M and Rodriguez-Seijas J. Comprehensive review on lactate metabolism in human health. 
Mitochondrion. 2014;17:76-100. 
8. Madias NE. Lactic acidosis. Kidney Int. 1986;29:752-74. 
9. Cingolani HE, Mattiazzi AR, Blesa ES and Gonzalez NC. Contractility in isolated mammalian heart muscle 
after acid-base changes. Circ Res. 1970;26:269-78. 
10. Fabiato A and Fabiato F. Effects of pH on the myofilaments and the sarcoplasmic reticulum of skinned 
cells from cardiace and skeletal muscles. J Physiol. 1978;276:233-55. 
11. Solaro RJ, Lee JA, Kentish JC and Allen DG. Effects of acidosis on ventricular muscle from adult and 
neonatal rats. Circ Res. 1988;63:779-87. 
12. Shapiro JI. Functional and metabolic responses of isolated hearts to acidosis: effects of sodium bicarbonate 
and Carbicarb. The American journal of physiology. 1990;258:H1835-9. 
13. Schotola H, Toischer K, Popov AF, Renner A, Schmitto JD, Gummert J, Quintel M, Bauer M, Maier LS 
and Sossalla S. Mild metabolic acidosis impairs the beta-adrenergic response in isolated human failing 
myocardium. Crit Care. 2012;16:R153. 
14. Kimmoun A, Ducrocq N and Levy B. New conclusive data on human myocardial dysfunction induced by 
acidosis. Crit Care. 2012;16:160. 
15. Shapiro JI. Pathogenesis of cardiac dysfunction during metabolic acidosis: therapeutic implications. Kidney 
international Supplement. 1997;61:S47-51. 
16. Shapiro JI, Whalen M and Chan L. Hemodynamic and hepatic pH responses to sodium bicarbonate and 
Carbicarb during systemic acidosis. Magn Reson Med. 1990;16:403-10. 
17. Suleymanlar G, Zhou HZ, McCormack M, Elkins N, Kucera R, Reiss OK and Shapiro JI. Mechanism of 
impaired energy metabolism during acidosis: role of oxidative metabolism. The American journal of 
physiology. 1992;262:H1818-22. 
18. Harrison SM, Frampton JE, McCall E, Boyett MR and Orchard CH. Contraction and intracellular Ca2+, 
Na+, and H+ during acidosis in rat ventricular myocytes. The American journal of physiology. 
1992;262:C348-57. 
19. Choi HS, Trafford AW, Orchard CH and Eisner DA. The effect of acidosis on systolic Ca2+ and 
sarcoplasmic reticulum calcium content in isolated rat ventricular myocytes. The Journal of physiology. 
2000;529 Pt 3:661-8. 
20. Sikes PJ, Zhao P, Maass DL, White J and Horton JW. Sodium/hydrogen exchange activity in sepsis and in 
sepsis complicated by previous injury: 31P and 23Na NMR study. Crit Care Med. 2005;33:605-15. 
21. DeSantiago J, Maier LS and Bers DM. Phospholamban is required for CaMKII-dependent recovery of Ca 
transients and SR Ca reuptake during acidosis in cardiac myocytes. J Mol Cell Cardiol. 2004;36:67-74. 
22. Wu LL, Tang C, Dong LW and Liu MS. Altered phospholamban-calcium ATPase interaction in cardiac 
sarcoplasmic reticulum during the progression of sepsis. Shock. 2002;17:389-93. 
67
Marshall Journal of Medicine, Vol. 1 [2015], Iss. 1, Art. 6
https://mds.marshall.edu/mjm/vol1/iss1/6
DOI: http://dx.doi.org/10.18590/mjm.2015.vol1.iss1.6
23. Dong LW, Wu LL, Ji Y and Liu MS. Impairment of the ryanodine-sensitive calcium release channels in the 
cardiac sarcoplasmic reticulum and its underlying mechanism during the hypodynamic phase of sepsis. 
Shock. 2001;16:33-9. 
24. Katz AM and Hecht HH. Editorial: the early "pump" failure of the ischemic heart. Am J Med. 1969;47:497-
502. 
25. Miller RG, Boska MD, Moussavi RS, Carson PJ and Weiner MW. 31P nuclear magnetic resonance studies 
of high energy phosphates and pH in human muscle fatigue. Comparison of aerobic and anaerobic exercise. 
J Clin Invest. 1988;81:1190-6. 
26. Kimmoun A, Novy E, Auchet T, Ducrocq N and Levy B. Hemodynamic consequences of severe lactic 
acidosis in shock states: from bench to bedside. Crit Care. 2015;19:175. 
27. Mitchell JH, Wildenthal K and Johnson RL, Jr. The effects of acid-base disturbances on cardiovascular and 
pulmonary function. Kidney international. 1972;1:375-89. 
28. Darby TD and Watts DT. ACIDOSIS AND BLOOD EPINEPHRINE LEVELS IN HEMORRHAGIC 
HYPOTENSION. The American journal of physiology. 1964;206:1281-4. 
29. Nahas GG, Zagury D, Milhaud A, Manger WM and Pappas GD. Acidemia and catecholamine output of the 
isolated canine adrenal gland. The American journal of physiology. 1967;213:1186-92. 
30. Nahas GG, Ligou JC and Mehlman B. Effects of pH changes on oxygen uptake and plasma catecholamine 
levels in the dog. The American journal of physiology. 1960;198:60-6. 
31. Campbell GS. Cardiac arrest: further studies on the effect of pH changes on vagal inhibition of the heart. 
Surgery. 1955;38:615-34. 
32. Cooper DJ, Walley KR, Wiggs BR and Russell JA. Bicarbonate does not improve hemodynamics in 
critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Annals of internal 
medicine. 1990;112:492-8. 
33. Teplinsky K, O'Toole M, Olman M, Walley KR and Wood LD. Effect of lactic acidosis on canine 
hemodynamics and left ventricular function. The American journal of physiology. 1990;258:H1193-9. 
34. Davies AO. Rapid desensitization and uncoupling of human beta-adrenergic receptors in an in vitro model 
of lactic acidosis. J Clin Endocrinol Metab. 1984;59:398-405. 
35. Kellum JA, Song M and Venkataraman R. Effects of hyperchloremic acidosis on arterial pressure and 
circulating inflammatory molecules in experimental sepsis. Chest. 2004;125:243-8. 
36. Orchard CH and Cingolani HE. Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res. 
1994;28:1312-9. 
37. Arieff AI, Leach W, Park R and Lazarowitz VC. Systemic effects of NaHCO3 in experimental lactic 
acidosis in dogs. The American journal of physiology. 1982;242:F586-91. 
38. Graf H, Leach W and Arieff AI. Evidence for a detrimental effect of bicarbonate therapy in hypoxic lactic 
acidosis. Science. 1985;227:754-6. 
39. Adler S, Roy A and Relman AS. Intracellular Acid-Base Regulation. I. The Response of Muscle Cells to 
Changes in Co2 Tension or Extracellular Bicarbonate Concentration. J Clin Invest. 1965;44:8-20. 
40. Kraut JA and Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev 
Nephrol. 2012;8:589-601. 
41. Shapiro JI, Whalen M, Kucera R, Kindig N, Filley G and Chan L. Brain pH responses to sodium 
bicarbonate and Carbicarb during systemic acidosis. The American journal of physiology. 
1989;256:H1316-21. 
42. Kindig NB, Sherrill DS, Shapiro JI and Filley GF. Extracorporeal bicarbonate space after bicarbonate or a 
bicarbonate-carbonate mixture in acidotic dogs. J Appl Physiol (1985). 1989;67:2331-4. 
43. Shapiro JI, Mathew A, Whalen M, Honigman B, Kaehny WD, Petty TL and Chan L. Different effects of 
sodium bicarbonate and an alternate buffer (Carbicarb) in normal volunteers. Journal of Critical Care. 
1990;5:157-160. 
44. Olson DE, Dart GA and Filley GF. Pressure drop and fluid flow regime of air inspired into the human lung. 
J Appl Physiol. 1970;28:482-94. 
45. Shapiro JI, Elkins N, Logan J, Ferstenberg LB and Repine JE. Effects of sodium bicarbonate, disodium 
carbonate, and a sodium bicarbonate/carbonate mixture on the PCO2 of blood in a closed system. J Lab 
Clin Med. 1995;126:65-9. 
46. Kimmoun A, Ducrocq N, Sennoun N, Issa K, Strub C, Escanye JM, Leclerc S and Levy B. Efficient extra- 
and intracellular alkalinization improves cardiovascular functions in severe lactic acidosis induced by 
hemorrhagic shock. Anesthesiology. 2014;120:926-34. 
68
Khitan, et al.: Alkali Therapy in Lactic Acidosis
Published by Marshall University's Joan C. Edwards School of Medicine, 2015
47. Allegretti AS, Flythe JE, Benda V, Robinson ES and Charytan DM. The effect of bicarbonate 
administration via continuous venovenous hemofiltration on acid-base parameters in ventilated patients. 
BioMed research international. 2015;2015:901590. 
48. Rocktaschel J, Morimatsu H, Uchino S, Ronco C and Bellomo R. Impact of continuous veno-venous 
hemofiltration on acid-base balance. Int J Artif Organs. 2003;26:19-25. 
49. Nahas GG, Sutin KM, Fermon C, Streat S, Wiklund L, Wahlander S, Yellin P, Brasch H, Kanchuger M, 
Capan L, Manne J, Helwig H, Gaab M, Pfenninger E, Wetterberg T, Holmdahl M and Turndorf H. 
Guidelines for the treatment of acidaemia with THAM. Drugs. 1998;55:191-224. 
50. Moon PF, Gabor L, Gleed RD and Erb HN. Acid-base, metabolic, and hemodynamic effects of sodium 
bicarbonate or tromethamine administration in anesthetized dogs with experimentally induced metabolic 
acidosis. American journal of veterinary research. 1997;58:771-6. 
51. Wildenthal K, Mierzwiak DS, Myers RW and Mitchell JH. Effects of acute lactic acidosis on left 
ventricular performance. The American journal of physiology. 1968;214:1352-9. 
52. Sirieix D, Delayance S, Paris M, Massonnet-Castel S, Carpentier A and Baron JF. Tris-hydroxymethyl 
aminomethane and sodium bicarbonate to buffer metabolic acidosis in an isolated heart model. American 
journal of respiratory and critical care medicine. 1997;155:957-63. 
53. Hoste EA, Colpaert K, Vanholder RC, Lameire NH, De Waele JJ, Blot SI and Colardyn FA. Sodium 
bicarbonate versus THAM in ICU patients with mild metabolic acidosis. Journal of nephrology. 
2005;18:303-7. 
54. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism: clinical and experimental. 
1989;38:1124-44. 
55. Wilkerson DP, Campbell IT, Blackwell JR, Berger NJ and Jones AM. Influence of dichloroacetate on 
pulmonary gas exchange and ventilation during incremental exercise in healthy humans. Respiratory 
physiology & neurobiology. 2009;168:224-9. 
56. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, Duncan CA, Harman 
EM, Henderson GN, Jenkinson S and et al. A controlled clinical trial of dichloroacetate for treatment of 
lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med. 1992;327:1564-
9. 
57. Filley GF and Kindig NB. Carbicarb, an alkalinizing ion-generating agent of possible clinical usefulness. 
Trans Am Clin Climatol Assoc. 1985;96:141-53. 
58. Li YC, Wiklund L and Bjerneroth G. Influence of alkaline buffers on cytoplasmic pH in myocardial cells 
exposed to hypoxia. Resuscitation. 1997;34:71-7. 
59. Li YC, Wiklund L, Tarkkila P and Bjerneroth G. Influence of alkaline buffers on cytoplasmic pH in 
myocardial cells exposed to metabolic acidosis. Resuscitation. 1996;32:33-44. 
60. Bersin RM and Arieff AI. Improved hemodynamic function during hypoxia with Carbicarb, a new agent 
for the management of acidosis. Circulation. 1988;77:227-33. 
61. Leung JM, Landow L, Franks M, Soja-Strzepa D, Heard SO, Arieff AI and Mangano DT. Safety and 
efficacy of intravenous Carbicarb in patients undergoing surgery: comparison with sodium bicarbonate in 
the treatment of mild metabolic acidosis. SPI Research Group. Study of Perioperative Ischemia. Critical 
care medicine. 1994;22:1540-9. 
62. Kolloffel WJ, de Vroom TE, Weekers LE and Woittiez AJ. Severe cutaneous side effects of peripheral 
infusions with carbicarb half strength. Intensive Care Med. 1994;20:531. 
 
69
Marshall Journal of Medicine, Vol. 1 [2015], Iss. 1, Art. 6
https://mds.marshall.edu/mjm/vol1/iss1/6
DOI: http://dx.doi.org/10.18590/mjm.2015.vol1.iss1.6
